Going forward, Henrik Birk will be in charge of Bavarian Nordic’s operational and HR strategies. He will take over the newly created position of Chief Operating Officer at the Danish-German biotech.
YposKesi, developer of gene and cell therapy products for rare diseases, has appointed Alain Lamproye as its CEO. Lamproye, an expert in industrial bioproduction, most recently served as Chairman of the BioPharma Business Unit of Novasep’s Belgian gene therapy subsidiary.
BenevolentAI has hired a Chief Medical Officer making it the first artificial intelligence company to do so. Patrick Keohane will take up position of CMO at BenevolentBio. The subsidiary of BenevolentAI aims to apply its AI to develop meds, and plans to find other uses for AI in bioscience as well.
German lab equipment provider Sartorius has appointed Rainer Lehmann to the Executive Board. Lehmann will be overseeing the Finance, Human Resources Management and Information Technology functions.
Henrik Luessen is taking over as Chief Business Officer at Promethera Biosciences SA, Belgian developer of cell-based meds. He will be responsible for identifying and executing strategic corporate development initiatives and licensing agreements.
Lund-based probiotics expert Probi AB has appointed Jörn Andreas as new CFO. He will replace Niklas Brandt, who in turn will take over responsibility for IT infrastructure and IR as CIO.
Pfizer’s Cyprus Business Manager Kyriakos Mikellis has been re-elected for the next two years as president of the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA).
Starting in May, Matthias Baumann will be new Chief Medical Officer of immunotherapy specialist Mologen AG. His primary goal will be preparing Mologen’s DNA cancer therapy lefitolimod for market launch.
Ex-Novartis Senior VP Judith Klimovsky has joined Copenhagen-based Genmab as Executive Vice President and Chief Development Officer. The appointment is meant to pave the way for the antibody specialist to grow into a global biotech company.
One Nucleus, the Cambridge-based not-for-profit membership organisation for international life science and healthcare companies, announced the appointment of Linda Summerton as a Director. Summerton is Chief Executive of Immodulon and a Senior Partner with TranScrip Partners.